
    
      Dose escalation and dose expansion to determine safety and tolerability of AZD3759, and
      explore RP2D in treatment of Chinese patients with EGFRm+ NSCLC with CNS metastasis. Two dose
      cohorts include: 150 and 250mg twice daily. Subjects will receive multiple doses of AZD3759
      for consecutively 21 days each cycle. Dose escalation is planned to be performed in a single
      center, and dose expansion in multiple centers.
    
  